EVALUATION OF PTGER4 GENE METHYLATION IN PLASMA FOR LUNG CANCER DETECTION

Phuong Ngoc Anh1,2, Dinh Van Luong1, Nguyen Van Ba3, Ho Huu Tho2,
1 Vietnam National Lung Hospital
2 Department of Genomics and Cytogenetics, Institute of Biomedicine and Pharmacy, Vietnam Military Medical University
3 Oncology Center, Military Hospital 103, Vietnam Military Medical University

Nội dung chính của bài viết

Tóm tắt

Objectives: To evaluate the diagnostic value of PTGER4 (Prostaglandin E Receptor 4) gene methylation in plasma for lung cancer detection compared to healthy controls. Methods: A cross-sectional, case-control study was conducted on 149 non-small cell lung cancer (NSCLC) patients and 100 healthy individuals. Peripheral blood samples were collected for PTGER4 methylation analysis using real-time methylation-specific PCR (MSP). Data were analyzed using SPSS 26.0, including group comparisons, receiver operating characteristic (ROC) analysis, and logistic regression. Results: The PTGER4 methylation positivity rate was significantly higher in lung cancer patients (18.8%) compared to healthy controls (3.0%, p < 0.001). PTGER4 methylation positivity increased the risk of lung cancer by 6.3 times (OR = 6.30; 95%CI: 1.90 - 20.40). The area under the ROC curve (AUC) was 0.58, with a sensitivity of 18.8% and a specificity of 97.0%. Conclusion: PTGER4 gene methylation is a promising biomarker for lung cancer detection. Despite its limited sensitivity, the high specificity suggests its potential as a confirmatory diagnostic tool, particularly when combined with imaging modalities such as low-dose computed tomography (LDCT).

Chi tiết bài viết

Tài liệu tham khảo

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263.
2. Phương Ngọc Anh, Đào Thùy Trang, Nguyễn Văn Ba và CS. Nghiên cứu bước đầu phân biệt ung thư phổi và bệnh phổi lành tính sử dụng dấu ấn methyl hóa gen SHOX2 từ mẫu sinh thiết phổi và mẫu sinh thiết lỏng. Tạp chí Y học Cộng đồng. 2022; 64(4):36-44.
3. Lea M Schotten, Kaid Darwiche, Michal Seweryn, et al. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules, and chronic obstructive pulmonary disease patients. European Journal of Cancer. 2021; 147:142-150.
4. Oudkerk M, Liu S, Heuvelmans MA, et al. Lung cancer LDCT screening and mortality reduction - evidence, pitfalls, and future perspectives. Nature Reviews Clinical Oncology. 2021; 18(3):135-151.
5. Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016 Sep 1; 8(9):a019505. DOI: 10.1101/cshperspect. a019505.
6. Hong Y, Kim WJ. DNA Methylation markers in lung cancer. Curr Genomics. 2021 Feb; 22(2):79-87. DOI: 10.2174/ 1389202921999201013164110.
7. Yokoyama U, Iwatsubo K, Umemura M, et al. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev. 2013; 65(3):1010-1052.
8. Wei B, Wu F, Xing W, et al. A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer. Sci Rep 11. 16782. 2021. https://doi.org/10.1038/ s41598-021-96242-6.
9. Weiss G, Schlegel A, Kottwitz D. et al. Validation of the SHOX2/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol. 2017 Jan; 12(1):77-84. https://doi.org/10.1016/ j.jtho.2016.08.123.